Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept)
  • Regulatory

FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept)

Big Molecule Watch

On April 2, 2026, Regeneron Pharmaceuticals announced that the U.S.

RegulatoryOphthalmologyRead full story

pharminent April 15, 2026

Big Molecule Watch

On April 2, 2026, Regeneron Pharmaceuticals announced that the U.S.

RegulatoryOphthalmologyRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Lilly to acquire CrossBridge Bio for up to $300m
Next: Travere wins long-awaited approval for kidney disease drug

Related Stories

  • Regulatory

FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients

pharminent June 2, 2026
  • Regulatory

FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy

pharminent June 1, 2026
  • Regulatory

Replimune gives cancer immunotherapy a third try after FDA leadership shakeup

pharminent May 29, 2026

You May Have Missed

  • Policy / Pricing

Eli Lilly issues data sharing ultimatum to 340B hospitals

pharminent June 2, 2026
  • M&A / Deals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

pharminent June 2, 2026
  • Clinical Data

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

pharminent June 2, 2026
  • Clinical Data

ASCO26: In vivo oncology approaches continue to show promise

pharminent June 2, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.